Oruka Therapeutics, Inc. (ORKA) Stock

Oruka Therapeutics, Inc. (ORKA) is a Healthcare stock trading at $72.42 (as of 2026-06-18), with a market capitalization of $3.53B and a trailing P/E of -127.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Oruka Therapeutics, Inc. is a biotechnology company developing monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immune (I&I) indications. Its development pipeline includes ORKA-001 and ORKA-002.

Valuation — source: SEC EDGAR (first-party)
Price$72.42
Market Cap$3.53B
P/E Ratio-127.2
EV / EBITDA-26.1
Price / Book7.25
DCF Value (model)$-29.44
DCF Upside vs Price-140.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$16.63M
Net Margin-634.0%
Return on Equity-23.9%
Current Ratio23.76
Revenue Growth (YoY)183.6%
FCF Growth (YoY)52.4%
Financial Health — source: SEC EDGAR
Altman Z-Score128.48 (safe)
Valuation vs Sector & Industry
Stock P/E-127.2
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-707.1%
vs Industry-837.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($364.51M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOLawrence Otto Klein
Employees28
CountryUS
IPO Date1997-08-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Biohaven Ltd. (BHVN)
  • uniQure N.V. (QURE)
  • Innoviva, Inc. (INVA)
  • Atai Beckley N.V (ATAI)
  • Precigen, Inc. (PGEN)
  • Relay Therapeutics, Inc. (RLAY)
  • Collegium Pharmaceutical, Inc. (COLL)
  • Rapport Therapeutics, Inc. Common Stock (RAPP)
ORKA earnings history · ORKA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.